You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

CLINICAL TRIALS PROFILE FOR NYX-783

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for NYX-783

Subscribe to access the full database, or Get Started Free
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT04044664 ↗	Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder	Completed	Massachusetts General Hospital	Phase 2	To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
NCT04044664 ↗	Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder	Completed	Premier Research Group plc	Phase 2	To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
NCT04044664 ↗	Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder	Completed	Aptinyx	Phase 2	To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.
NCT05181995 ↗	Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD	Recruiting	Worldwide Clinical Trials	Phase 2/Phase 3	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
NCT05181995 ↗	Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD	Recruiting	Aptinyx	Phase 2/Phase 3	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
NCT05447286 ↗	Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study	Not yet recruiting	National Institute on Drug Abuse (NIDA)	Phase 1	This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current recreational use.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for NYX-783

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Post-Traumatic Stress Disorder	1
PTSD	1
Opioid Use Disorder	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Opioid-Related Disorders	1
Stress Disorders, Traumatic	1
Stress Disorders, Post-Traumatic	1
Disease	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for NYX-783

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	21
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Florida	2
Connecticut	2
Washington	1
Texas	1
Tennessee	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for NYX-783

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 2	1
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for NYX-783

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Aptinyx	2
Premier Research Group plc	1
Worldwide Clinical Trials	1
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	3
Other	3
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.